These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7000685)

  • 1. Relationship of anti-tuberculous protection to lung granuloma produced by intravenous injection of synthetic 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kakinuma M; Kato K; Okuyama H; Azuma I
    Immunology; 1980 Aug; 40(4):557-64. PubMed ID: 7000685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
    Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelioid granuloma formation by a synthetic bacterial cell wall component, muramyl dipeptide (MDP).
    Tanaka A; Emori K
    Am J Pathol; 1980 Mar; 98(3):733-48. PubMed ID: 6767407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.
    Tree JA; Williams A; Clark S; Hall G; Marsh PD; Ivanyi J
    Clin Exp Immunol; 2004 Dec; 138(3):405-9. PubMed ID: 15544615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of C3H mice to develop lung granuloma after intravenous injection of BCG cell wall vaccine. Demonstration of a defect in lymphoid cells.
    Kakinuma M; Onoé K; Okada M; Kimura T; Kato K; Okuyama H; Morikawa K; Yamamoto K
    Immunology; 1981 May; 43(1):1-9. PubMed ID: 6972900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of pulmonary granuloma formation in mice by treatment with Mycobacterial protoplasm and immuno-suppressants and its relation to protection against aerosol infection with virulent Mycobacterium tuberculosis.
    Yamamoto K; Granger DL; Brehmer W; Azuma I; Ribi E
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 250(1-2):127-41. PubMed ID: 6797153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1991 Dec; 66(12):811-7. PubMed ID: 1784098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant activity of 6-O-mycoloyl-N-acetylmuramuyl-L-alanyl-D-isoglutamine.
    Yamamura Y; Azuma I; Sugimura K; Yamawaki M; Uemiya M
    Gan; 1976 Dec; 67(6):867-77. PubMed ID: 828599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoadjuvant activities of synthetic 6-O-acyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes.
    Kotani S; Kinoshita F; Morisaki I; Shimono T; Okunaga T; Takada H; Tsujimoto M; Watanabe Y; Kato K; Shiba T; Kusumoto S; Okada S
    Biken J; 1977 Dec; 20(3-4):95-103. PubMed ID: 614856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice.
    Fan X; Gao Q; Fu R
    Scand J Immunol; 2007 Nov; 66(5):523-8. PubMed ID: 17916110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
    Azuma I; Sugimura K; Yamawaki M; Uemiya M; Kusumoto S; Okada S; Shiba T; Yamamura Y
    Infect Immun; 1978 Jun; 20(3):600-7. PubMed ID: 97234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
    Staruch MJ; Wood DD
    J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and protective activity of beta-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine with alkylalicyclic and arylaliphatic aglycons].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2005; 31(6):637-44. PubMed ID: 16363137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide).
    Ribi EE; Cantrell JL; Von Eschen KB; Schwartzman SM
    Cancer Res; 1979 Nov; 39(11):4756-9. PubMed ID: 115579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular regulation of lung granuloma formation and delayed- type hypersensitivity induced with BCG cell walls. Further evidence of involvement of cellular immunity in lung granuloma formation.
    Yamamoto K; Kato K; Kakinuma M; Brehmer W
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Mar; 251(3):357-68. PubMed ID: 7043952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A chemical structure in tuberculous bacilli responsible for epithelioid granuloma formation (proceedings)].
    Emori K; Tanaka A
    Bull Int Union Tuberc; 1979 Jun; 54(2):176. PubMed ID: 118786
    [No Abstract]   [Full Text] [Related]  

  • 19. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats.
    Kohashi O; Aihara K; Ozawa A; Kotani S; Azuma I
    Lab Invest; 1982 Jul; 47(1):27-36. PubMed ID: 7087395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.